4 Healthcare Stock Stories for Thursday Investment Wellness

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Eli Lilly and Co. (NYSE:LLY): Closing price $49.92

Lilly anticipates the loss of roughly 20 percent of its global revenue in 2014 due to the expiry of key drug patents, and so is suspending base pay increases for the majority of its employees next year to lower costs. At the end of 2013, Lilly’s current largest product, the antidepressant Cymbalta, will lose patent protection, while copied forms of its $1 billion a year Evista osteoporosis drug should emerge in early 2014. The company has also elected to reduce employee bonuses paid out in 2015 for next year.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

LLY

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business